Inflammatory bowel disease. Inflammatory polyps of colon with intestinal obstruction
Conditions
Interventions
Intervention 1: Intervention group: The intervention group receiving resveratrol supplements will receive two 75 mg supplements daily for 12 weeks due to the better effectiveness of this supplement at
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
8 Years to 18 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate and sign the informed consent form after full knowledge of the objectives and methods of the study. Girls and boys aged 8 to 18 years. Diagnosis of IBD based on endoscopic, laboratory studies, and clinical examinations. Absences other diseases and chronic and acute liver disorders (hepatitis B, C, etc.), biliary disease, other gastrointestinal diseases, chronic diseases (including type one or two diabetes, cardiovascular, pulmonary and celiac disease), autoimmune diseases Known and inherited and metabolic disorders. No history of alcohol consumption or alcohol consumption more than 10 grams per day in women and more than 20 grams per day in men. No pregnancy or breastfeeding in women. No substance abuse, no chronic inflammatory disease, no history of cancer, no hormone therapy, no recent weight loss diet. No history of gastrointestinal surgery. Do not take medications or supplements that affect appetite, weight, or metabolism for at least 6 months before the study (such as medications that affect carbohydrate, protein, or fat metabolism, and medications that reduce or increase appetite or food intake, including herbal supplements).
Exclusion criteria
Exclusion criteria: Having any acute illness The occurrence of any accident that affects a person's health. Use of antibiotics during the study Acceptance rate less than 80% Immigration Exclusion based on personal preference of participants or their parents Changes in medications taken during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity index. Timepoint: Beginning and end of the study. Method of measurement: Software for calculating pediatric Crohn's disease activity index (PCDAI) and pediatric ulcerative colitis activity index (PUCAI).;Serum C-reactive protein (CRP) levels. Timepoint: Beginning and end of the study. Method of measurement: Laboratory kit.;Serum tumor necrosis factor (TNF) levels. Timepoint: Beginning and end of the study. Method of measurement: Laboratory kit.;Serum total antioxidant capacity (TAC) levels. Timepoint: Beginning and end of the study. Method of measurement: Laboratory kit.;Serum malondialdehyde (MDA) levels. Timepoint: Beginning and end of the study. Method of measurement: Laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Beginning and end of the study. Method of measurement: scale.;Body mass index. Timepoint: Beginning and end of the study. Method of measurement: Calculation.;Serum Albumin. Timepoint: Beginning and end of the study. Method of measurement: Laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPejman Rohani
Tehran University of Medical Sciences
Outcome results
None listed